-
Biotech Decliners: JUNO THERAPEUTICS (NASDAQ:JUNO), Cytokinetics (NASDAQ:CYTK), NeuroDerm (NASDAQ:NDRM), Trevena (NASDAQ:TRVN), Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Juno Therapeutics (NASDAQ:JUNO) major shareholder Douglas K. Bratton bought 625,000 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average price of $24.00 per share, for a total transaction of $15,000,000.00. JUNO THERAPEUTICS, INC. (NASDAQ:JUNO) in last trading activity decreased -7.60% to close at $48.25.…
-
Investor’s Choice: JUNO THERAPEUTICS (NASDAQ:JUNO), AK Steel Holding Corporation (NYSE:AKS), Atlantic Tele-Network (NASDAQ:ATNI), Zhaopin (NYSE:ZPIN), Johnson & Johnson (NYSE:JNJ)
In 2015, Seattle’s rising star biotech company JUNO THERAPEUTICS, INC. (NASDAQ:JUNO) will have to put its money where its mouth is in terms of developing scalable, commercial cancer treatments. Juno made waves in 2014 as it raisedmassive amounts of venture capital funding , produced promising clinical trial results boasting up to 91 percent cancer cure…
-
Traders Alert: JUNO THERAPEUTICS (NASDAQ:JUNO), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), SodaStream International (NASDAQ:SODA), STAG Industrial (NYSE:STAG), Rite Aid Corporation (NYSE:RAD)
On December 23, 2014, Juno Therapeutics, Inc.’s (NASDAQ:JUNO) amended and restated certificate of incorporation filed with the Secretary of State of the State of Delaware and its amended and restated bylaws became effective in connection with the closing of the initial public offering of shares of the Company’s common stock JUNO THERAPEUTICS, INC. (NASDAQ:JUNO) in…
-
Market Watch: Key Energy Services Inc. (NYSE:KEG), JUNO THERAPEUTICS (NASDAQ:JUNO), HCI Group (NYSE:HCI), Google Inc (NASDAQ:GOOGL), Abbott Laboratories (NYSE:ABT)
On December 26, Key Energy Services Inc. (NYSE:KEG) oil names lower as crude moves back into negative territory on supply and demand concerns. Key Energy Services Inc. (NYSE:KEG) in last trading activity fell -10.22% to close at $1.67. Company weekly performance is -2.91% while its quarterly performance stands at -65.35%. Key Energy Services Inc. (NYSE:KEG)…
-
Investors Are Eying: JUNO THERAPEUTICS (NASDAQ:JUNO), Petroleo Brasileiro Petrobras (NYSE:PBR-A), Wolverine Bancorp (NASDAQ:WBKC), Orbital Sciences Corp. (NYSE:ORB), Gilead Sciences (NASDAQ:GILD)
Juno Therapeutics, Inc. (NASDAQ:JUNO) on 23 December announced the closing of its initial public offering of 12.7 million shares of common stock at a price to the public of $24.00 per share, which includes the exercise in full by the underwriters of the offering of their option to purchase 1.7 million shares. JUNO THERAPEUTICS, INC.…
-
Biotech Bearish Stocks: Actinium Pharmaceuticals (NYSEMKT:ATNM), JUNO THERAPEUTICS (NASDAQ:JUNO), Calithera Biosciences (NASDAQ:CALA), Ardelyx (NASDAQ:ARDX), Immune Design Corp. (NASDAQ:IMDZ)
Actinium Pharmaceuticals, Inc (NYSEMKT:ATNM) a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced on 3 December that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is…
-
Investors Are Eying: JUNO THERAPEUTICS (NASDAQ:JUNO), Petroleo Brasileiro Petrobras (NYSE:PBR-A), The Spectranetics (NASDAQ:SPNC), Atlas Resource Partners, L.P. (NYSE:ARP), PCL
Juno Therapeutics (NASDAQ:JUNO) major shareholder Douglas K. Bratton bought 625,000 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were purchased at an average price of $24.00 per share, for a total transaction of $15,000,000.00. JUNO THERAPEUTICS, INC. (NASDAQ:JUNO) in last trading activity fell -5.22% to close at $51.38.…
-
Market Watch List: JUNO THERAPEUTICS (NASDAQ:JUNO), Groupon (NASDAQ:GRPN), CoreSite Realty Corporation (NYSE:COR), Magal Security Systems (NASDAQ:MAGS), Cellular Dynamics International (NASDAQ:ICEL)
Juno Therapeutics (NASDAQ:JUNO) major shareholder Douglas K. Bratton bought 625,000 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The stock was purchased at an average price of $24.00 per share, for a total transaction of $15,000,000.00. JUNO THERAPEUTICS, INC. (NASDAQ:JUNO) in last trading activity increased 11.25% to close at $54.21.…
-
Premarket Active Stocks: American Realty Capital Properties (NASDAQ:ARCP), NeuroDerm (NASDAQ:NDRM), Apple Inc. (NASDAQ:AAPL), GoPro (NASDAQ:GPRO), JUNO THERAPEUTICS (NASDAQ:JUNO)
Activist investor Keith Meister’s hedge fund firm, Corvex Management LP, disclosed in a regulatory filing that it accumulated 64.70 million shares or a 7.1% stake, in American Realty Capital Properties, Inc. (NASDAQ:ARCP). American Realty Capital Properties, Inc. (NASDAQ:ARCP) in last trading activity advanced 2.17% to close at $8.48. Company weekly performance is 5.74% while its…
-
Stock in News: Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR), JUNO THERAPEUTICS (NASDAQ:JUNO), Pingtan Marine Enterprise (NASDAQ:PME), Chevron Corporation (NYSE:CVX), Amazon.com (NASDAQ:AMZN)
On December 23, Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced that the Company has entered into a Manufacturing and Clinical Trial Agreement with the University of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. The studies are expected to commence early next year,…